Andrew Arno - 23 Jun 2023 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
Director
Signature
/s/ Andrew Arno
Issuer symbol
OCX
Transactions as of
23 Jun 2023
Net transactions value
$0
Form type
4
Filing time
27 Jun 2023, 21:30:20 UTC
Previous filing
05 Apr 2023
Next filing
27 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCX Common Stock, no par value Award $0 +30,000 +4.5% $0.000000 703,133 23 Jun 2023 Direct F1
holding OCX Common Stock, no par value 156,084 23 Jun 2023 See footnote F2
holding OCX Common Stock, no par value 156,084 23 Jun 2023 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +135,000 $0.000000 135,000 23 Jun 2023 Common Stock 135,000 $0.2000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.
F2 These shares of the Issuer's common stock, no par value ("Common Stock"), are held by JBA Investments LLC ("JBA"). The Reporting Person is the Manager of JBA and in such capacity has the right to vote and dispose of securities held by JBA.
F3 These shares of Common Stock are held by MJA Investments LLC ("MJA"). The Reporting Person is the Manager of MJA and in such capacity has the right to vote and dispose of securities held by MJA.
F4 Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.